What is the best salvage therapy for Hodgkin lymphoma? Review
| Authors: | Luttwak, E.; Moskowitz, A. J. |
| Review Title: | What is the best salvage therapy for Hodgkin lymphoma? |
| Abstract: | Purpose of reviewHistorically, salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant (HDT/ASCT) was the mainstay approach for relapsed or refractory classic HL. The emergence of novel agents for HL, such as brentuximab vedotin and programmed death-1 (PD-1) blockade has revolutionized therapeutic strategies, yielding excellent results. This review aims to provide a comprehensive overview of new salvage therapies and offer insights into forthcoming therapeutic options.Recent findingsThe incorporation of brentuximab vedotin and PD-1 blockade into salvage therapy before HDT/ASCT has led to markedly improved outcomes. Notably, PD-1 based salvage studies yield posttransplant 2-year progression-free survival rates approaching 90%, marking a significant advancement in the treatment of Hodgkin lymphoma (HL). Studies are beginning to explore nontransplant treatment approaches following front-line treatment failure and may identify certain risk groups eligible for these strategies.SummaryThe landscape of HL treatment is rapidly evolving, leading to significant changes in the standard of care. Novel agents are now administered earlier in the disease course, resulting in higher cure rates. The focus of treatment is shifting towards achieving cure with minimal toxicity, reducing exposure to various agents, and advancing research in optimizing treatment sequencing and patient selection for less intensive therapies. © 2024 Wolters Kluwer Health, Inc. All rights reserved. |
| Keywords: | survival rate; treatment failure; review; salvage therapy; drug megadose; antineoplastic agent; progression free survival; multiple cycle treatment; antineoplastic combined chemotherapy protocols; randomized controlled trials as topic; hematopoietic stem cell transplantation; hodgkin disease; drug dose; phase 1 clinical trial; high risk population; drug therapy; transplantation, autologous; therapy; pharmacology; hodgkin lymphoma; classical hodgkin lymphoma; randomized controlled trial (topic); autotransplantation; relapsed/refractory; procedures; salvage chemotherapy; immune checkpoint inhibitor; brentuximab vedotin; humans; human; programmed death-1; immune checkpoint inhibitors; high dose chemotherapy and autologous stem cell transplant |
| Journal Title: | Current Opinion in Oncology |
| Volume: | 36 |
| Issue: | 5 |
| ISSN: | 1040-8746 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2024-09-01 |
| Start Page: | 346 |
| End Page: | 352 |
| Language: | English |
| DOI: | 10.1097/cco.0000000000001073 |
| PUBMED: | 39007229 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- MSK corresponding author is Alison Moskowitz -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work